Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment.
This is good news for Genfit, which managed to kickstart a phase III trial for their lead candidate, Elafibranor, just one year after the read-out of the phase IIb results.
There is, of course, much expectation regarding the clinical development of this candidate. Non-alcoholic steatohepatitis (NASH) is a disease on the rise, linked to diabetes and obesity. It already affects about 30 million people worldwide – who have no treatment option so far.